Personalized medicine & survival prediction

In this episode, Alice Limonciel and Robert Nagourney discuss the benefits of looking into phenotype rather than genotype when studying cancer, how metabolomics contributes to the patient’s journey through personalized medicine, and the ways that survival prediction can be interpreted.

Robert Nagourney

Robert A. Nagourney, MD, is Medical and Laboratory Director of The Nagourney Cancer Institute in Long Beach, California, Associate Clinical Professor, at University of California Irvine and founder and CEO of Metabolomycs, Inc.  He is board certified in internal medicine, medical oncology, and hematology.

Favorite metabolite

Learn more about his work
Nagourney Cancer Institute |

Metabolomycs |

TEDx talk |

Paper we discuss in this episode
Ovarian cancer | Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis

Pancreatic cancer | Diagnostic and Prognostic Performance of Metabolic Signatures in Pancreatic Ductal Adenocarcinoma: The Clinical Application of Quantitative NextGen Mass Spectrometry

Sign up for The Metabolomist mailing list to be the first to hear about the latest episodes and news around metabolomics at

Finally available – Alices first book
The STORY principle – A guide to the biological interpretation of metabolomics
Also featuring some of the Metabolomists from Season 1
Available on Amazon and the biocrates webshop